Burning Rock Biotech Ltd (BNR NASDAQ) stock market data APIs

Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS) based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various cancer types, including pan-cancer, lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, and ovarian cancer. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples, and OncoCompass, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore, which assesses microsatellite loci related to MSI status and detects mutations in genes associated with gastrointestinal cancers. It also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of the key products. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.